ARS Pharmaceuticals, Inc

Lician Pro · $19.99/mo or $149/yr · AAPL vs MSFT

ARS Pharmaceuticals, Inc (SPRY) SEC filings

ARS Pharmaceuticals, Inc (SPRY) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported SPRY revenue for 2025-12-31 was $84.3M. Net income was -$171.3M. Revenue was down 5.5% from 2024-12-31 to 2025-12-31. SPRY currently screens at market cap $983.1M. The SPRY filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what ARS Pharmaceuticals, Inc said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.

Earnings & events

All events

Event insights for SPRY — what management said, what changed, and why it matters.

Recent filings

These filings as JSON? API free 100/day

SPRY SEC filings FAQ

What is the latest SPRY SEC filing?

The latest cached ARS Pharmaceuticals, Inc (SPRY) filing on this page is 8-K · Jul 17, 2026. Filings: https://lician.com/sec/spry

What is the latest SPRY filing accession number?

The latest cached ARS Pharmaceuticals, Inc (SPRY) accession number on this page is 0001193125-26-307773. Filing: https://lician.com/sec/spry/0001193125-26-307773

Which item code is on the latest SPRY filing?

Cached item code on the latest ARS Pharmaceuticals, Inc (SPRY) 8-K is 5.02.

How many SPRY SEC filings are listed on this page?

This page lists 3 cached ARS Pharmaceuticals, Inc (SPRY) SEC filings. Filings: https://lician.com/sec/spry

What events are listed on the SPRY SEC page?

Cached event headlines on this ARS Pharmaceuticals, Inc (SPRY) SEC page: "SPRY earnings". Events: https://lician.com/sec/spry

What are SPRY's latest revenue and net income?

Latest cached ARS Pharmaceuticals, Inc (SPRY) revenue for Dec 31, 2025 was $84.3M. Net income was -$171.3M. Statements: https://lician.com/financials/spry